Novavax, Inc., together with its subsidiary, Novavax AB, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants. Its lead adjuvant is Matrix-M that is used to enable a vaccine to enhance the amplitude of the immune response and qualitatively change it, enhance its specificity to provide protection against related microorganisms, as well as allows immunization with much lower doses of antigen. The company develops respiratory syncytial (RSV) virus fusion protein nanoparticle vaccine candidate for infants via maternal immunization in Phase III clinical trial; older adults in Phase II clinical trial; and children six months to five years of age in Phase I clinical trial. Novavax, Inc. also develops NanoFlu vaccine, which is in Phase I/II clinical trial for treating seasonal influenza in older adults; and Ebola virus glycoprotein vaccine that is in Phase I clinical trial. Its preclinical programs include Zika virus; combination respiratory vaccine candidate to protect against RSV and seasonal influenza, as well as other infectious disease vaccine candidates. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:NVAX
Previous Symbol
CUSIP67000210
Phone240-268-2000
Debt
Debt-to-Equity RatioN/A
Current Ratio3.44
Quick Ratio3.44
Price-To-Earnings
Trailing P/E Ratio-3.60
Forward P/E Ratio-4.37
P/E GrowthN/A
Sales & Book Value
Annual Sales$31.18 million
Price / Sales27.87
Cash FlowN/A
Price / Cash FlowN/A
Book Value($0.31) per share
Price / Book-7.32
Profitability
EPS (Most Recent Fiscal Year)($0.63)
Net Income$-183,760,000.00
Net Margins-482.87%
Return on EquityN/A
Return on Assets-66.83%
Miscellaneous
Employees347
Outstanding Shares382,850,000
Market Cap$922.67 million
OptionableOptionable
Novavax (NASDAQ:NVAX) Frequently Asked Questions
What is Novavax's stock symbol?
Novavax trades on the NASDAQ under the ticker symbol "NVAX."
How were Novavax's earnings last quarter?
Novavax, Inc. (NASDAQ:NVAX) announced its earnings results on Wednesday, November, 7th. The biopharmaceutical company reported ($0.12) EPS for the quarter, hitting the Zacks' consensus estimate of ($0.12). The biopharmaceutical company earned $7.70 million during the quarter, compared to the consensus estimate of $9.63 million. Novavax's revenue for the quarter was down 8.3% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.15) earnings per share. View Novavax's Earnings History.
When is Novavax's next earnings date?
What price target have analysts set for NVAX?
10 brokers have issued 12 month target prices for Novavax's shares. Their forecasts range from $1.35 to $10.00. On average, they expect Novavax's share price to reach $3.6780 in the next year. This suggests a possible upside of 62.0% from the stock's current price. View Analyst Price Targets for Novavax.
What is the consensus analysts' recommendation for Novavax?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novavax in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Novavax.
Has Novavax been receiving favorable news coverage?
News coverage about NVAX stock has trended negative recently, InfoTrie Sentiment reports. InfoTrie scores the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Novavax earned a media sentiment score of -2.4 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 5.0 out of 10, indicating that recent media coverage is somewhat likely to have an effect on the stock's share price in the next several days.
Are investors shorting Novavax?
Novavax saw a increase in short interest during the month of November. As of November 30th, there was short interest totalling 57,186,677 shares, an increase of 4.1% from the November 15th total of 54,925,981 shares. Based on an average trading volume of 5,356,172 shares, the short-interest ratio is presently 10.7 days. Approximately 15.1% of the company's stock are short sold. View Novavax's Current Options Chain.
Who are some of Novavax's key competitors?
Some companies that are related to Novavax include argenx (ARGX), Allogene Therapeutics (ALLO), Repligen (RGEN), China Biologic Products (CBPO), Halozyme Therapeutics (HALO), Acceleron Pharma (XLRN), Denali Therapeutics (DNLI), Atara Biotherapeutics (ATRA), Aerie Pharmaceuticals (AERI), Crispr Therapeutics (CRSP), Regenxbio (RGNX), Spark Therapeutics (ONCE), Editas Medicine (EDIT), Rubius Therapeutics (RUBY) and Autolus Therapeutics (AUTL).
Who are Novavax's key executives?
Novavax's management team includes the folowing people:
- Mr. Stanley Charles Erck, Pres, CEO & Director (Age 70)
- Mr. John Joseph Trizzino, Sr. VP, Chief Bus. Officer, CFO & Treasurer (Age 58)
- Mr. John A. Herrmann III, Sr. VP, Gen. Counsel & Corp. Sec. (Age 52)
- Dr. Gregory M. Glenn, Pres of R&D (Age 64)
- Ms. Jill Hoyt, VP of HR & Admin.
Who are Novavax's major shareholders?
Novavax's stock is owned by a number of of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (5.83%), Vanguard Group Inc (5.83%), Baker BROS. Advisors LP (1.23%), Pictet Asset Management Ltd. (0.78%), Bank of New York Mellon Corp (0.47%) and Panagora Asset Management Inc. (0.28%). Company insiders that own Novavax stock include Barclay A Phillips, Gregory M Glenn, James F Young, John A Herrmann III, John Trizzino, Michael A Mcmanus Jr and Stanley C Erck. View Institutional Ownership Trends for Novavax.
Which institutional investors are selling Novavax stock?
NVAX stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Virtus ETF Advisers LLC, GSA Capital Partners LLP, Credit Suisse AG, TIAA CREF Investment Management LLC, AQR Capital Management LLC and Creative Planning. View Insider Buying and Selling for Novavax.
Which institutional investors are buying Novavax stock?
NVAX stock was acquired by a variety of institutional investors in the last quarter, including Baker BROS. Advisors LP, Pictet Asset Management Ltd., Vanguard Group Inc, Vanguard Group Inc., Panagora Asset Management Inc., Paloma Partners Management Co, Connor Clark & Lunn Investment Management Ltd. and Swiss National Bank. Company insiders that have bought Novavax stock in the last two years include Barclay A Phillips, Gregory M Glenn, John A Herrmann III, John Trizzino, Michael A Mcmanus Jr and Stanley C Erck. View Insider Buying and Selling for Novavax.
How do I buy shares of Novavax?
Shares of NVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Novavax's stock price today?
One share of NVAX stock can currently be purchased for approximately $2.27.
How big of a company is Novavax?
Novavax has a market capitalization of $922.67 million and generates $31.18 million in revenue each year. The biopharmaceutical company earns $-183,760,000.00 in net income (profit) each year or ($0.63) on an earnings per share basis. Novavax employs 347 workers across the globe.
What is Novavax's official website?
How can I contact Novavax?
Novavax's mailing address is 20 FIRSTFIELD ROAD, GAITHERSBURG MD, 20878. The biopharmaceutical company can be reached via phone at 240-268-2000 or via email at [email protected]
MarketBeat Community Rating for Novavax (NASDAQ NVAX)
MarketBeat's community ratings are surveys of what our community members think about Novavax and other stocks. Vote "Outperform" if you believe NVAX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVAX will underperform the S&P 500 over the long term. You may vote once every thirty days.
